KPTI - Karyopharm Therapeutics Inc Stock Price, Fair Value and News

0.98USD+0.02 (+2.08%)Market Closed

Market Summary

USD0.98+0.02

Market Closed

2.08%

KPTI Stock Price

View Fullscreen

KPTI RSI Chart

KPTI Valuation

Market Cap

115.4M

Price/Earnings (Trailing)

-0.79

Price/Sales (Trailing)

0.82

EV/EBITDA

-0.7

Price/Free Cashflow

-0.98

KPTI Price/Sales (Trailing)

KPTI Profitability

EBT Margin

-103.94%

Return on Equity

86.61%

Return on Assets

-71.57%

Free Cashflow Yield

-102.06%

KPTI Fundamentals

KPTI Revenue

Revenue (TTM)

140.5M

Rev. Growth (Yr)

-14.4%

Rev. Growth (Qtr)

-1.84%

KPTI Earnings

Earnings (TTM)

-146.3M

Earnings Growth (Yr)

-9.48%

Earnings Growth (Qtr)

10.7%

Breaking Down KPTI Revenue

Last 7 days

10.1%

Last 30 days

-2%

Last 90 days

-7.5%

Trailing 12 Months

-42.0%

How does KPTI drawdown profile look like?

KPTI Financial Health

Current Ratio

3.04

KPTI Investor Care

Shares Dilution (1Y)

3.25%

Diluted EPS (TTM)

-1.27

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	140.5M	0	0	0
2023	148.1M	146.0M	145.9M	146.0M
2022	234.2M	251.3M	249.8M	157.1M
2021	113.2M	102.3M	118.7M	209.8M
2020	58.9M	82.9M	91.1M	108.1M
2019	33.0M	35.6M	38.3M	40.9M
2018	16.5M	31.4M	31.7M	30.3M
2017	222.0K	567.8K	1.3M	1.6M
2016	0	309.0K	207.0K	179.0K
2015	0	208.0K	262.0K	266.0K
2014	325.0K	213.0K	234.0K	229.0K
2013	833.0K	433.0K	399.0K	387.0K
2012	272.5K	393.0K	513.5K	634.0K
2011	0	0	0	152.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Karyopharm Therapeutics Inc

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

CEO	Mr. Richard A. Paulson M.B.A.
WEBSITE	karyopharm.com
INDUSTRY	Biotechnology
EMPLOYEES	385

Karyopharm Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Karyopharm Therapeutics Inc? What does KPTI stand for in stocks?

KPTI is the stock ticker symbol of Karyopharm Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Karyopharm Therapeutics Inc (KPTI)?

As of Fri Jul 26 2024, market cap of Karyopharm Therapeutics Inc is 115.36 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KPTI stock?

You can check KPTI's fair value in chart for subscribers.

Is Karyopharm Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether KPTI is over valued or under valued. Whether Karyopharm Therapeutics Inc is cheap or expensive depends on the assumptions which impact Karyopharm Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KPTI.

What is Karyopharm Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, KPTI's PE ratio (Price to Earnings) is -0.79 and Price to Sales (PS) ratio is 0.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KPTI PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Karyopharm Therapeutics Inc's stock?

In the past 10 years, Karyopharm Therapeutics Inc has provided -0.302 (multiply by 100 for percentage) rate of return.